The U.S. pharmaceutical cold chain is under pressure as growth in mRNA, CAR-T and precision biologics outpaces temporary storage capacity. Annual losses near $35 billion are attributed to cold-chain failures.
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
